High cardiovascular risk patients need reduction of low-density-lipoprotein cholesterol (LDL-C) to <70 mg/dL (1.8 mmol/L). Statins are optimal treatment but myopathy can be a limitation to their use. The incidence of statin-related myopathy is difficult to determine but up to 10.5% appears an appropriate estimate. Short-term trials report lower incidence than long-term trials. Statin-related myopathy may be influenced by genetics and tends to be dose-dependent. Ezetimibe can contribute to LDL-C reduction allowing a lower dose of statin to be used. Another approach is to administer rosuvastatin twice weekly. Statins have been shown to interfere with the cellular role of coenzyme Q10. Coenzyme Q10 supplementation may decrease or prevent statin myopathy, but this has not been proven. The occurrence of the most serious complication of myopathy—rhabdomyolysis—is very rare, but awareness of the problem, risks, and prevention are essential.
Phillips PS, Haas RH, Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels . Ann Intern Med. 2002; 137(7):581-585.
3.
Joy TR, Hegele RANarrative review: statin-related myopathy. Ann Intern Med . 2009;150(12):858-868.
4.
Nichols GA, Koro CEDoes statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther . 2007;29(8):1761-1770.
5.
Bruckert E., Hayem G., Dejager S., Yau C., Begaud B.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403-414.
6.
Harper CR, Jacobson TAThe broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007;18(4): 401-408.
7.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
8.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339(19):1349-1357.
9.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ; 335(14):1001-1009.
10.
Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301-1307.
11.
Nissen SE, Tuzcu EM, Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial . JAMA. 2004;291(9):1071-1080.
12.
Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ;350(15):1495-1504.
13.
Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565.
14.
Silva M., Matthews ML, Jarvis C., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29(2):253-260.
15.
Josan K., Majumdar SR, McAlister FAThe efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178(5):576-584.
16.
Newman C., Tsai J., Szarek M., Luo D., Gibson E.Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006; 97(1):61-67.
17.
Thompson PD , Clarkson P., Karas RHStatin-associated myopathy. JAMA. 2003;289(13):1681-1690.
18.
Wortmann RLDose-related statin myopathy: is it an issue ? Cleve Clin J Med. 2005;72(9):751-753, 756.
19.
Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study . N Engl J Med. 2008; 359(8):789-799.
20.
Arnaboldi L. , Corsini A.Do structural differences in statins correlate with clinical efficacy? Curr Opin Lipidol. 21(4):298-304.
21.
Bolego C., Baetta R., Bellosta S., Corsini A., Paoletti R.Safety considerations for statins. Curr Opin Lipidol. 2002;13(6):637-644.
22.
Bosch X., Poch E., Grau JMRhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62-72.
23.
Melli G., Chaudhry V., Cornblath DRRhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005; 84(6):377-385.
24.
Veenstra J. , Smit WM, Krediet RT, Arisz L.Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant. 1994;9(6):637-641.
25.
Staffa JA, Chang J., Green L.Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346(7):539-540.
26.
Wensel TM, Waldrop BA, Wensel B.Pitavastatin: a new HMG-CoA reductase inhibitor. Ann Pharmacother.2010; 44(3):507-514.
27.
Brewer HB, Jr.Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams . Am J Cardiol. 2003;92(4B):23K-29K.
28.
Sukhija R., Aronow WS, Yalamanchili K., Peterson SJ, Frishman WH, Babu S.Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology. 2005;103(3):158-160.
29.
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 2004;110(2): 227-239.
30.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
31.
Whayne TF, Jr.A viewpoint on statin effects-benefits and problems . Int J Angiol. 2008;17(1):178-180.
32.
Lexchin J.Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. Health Policy. 2009 ;91(2):142-147.
33.
Schwartz GG , Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
34.
Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-160.
35.
LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
36.
Gagne C., Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10): 1084-1091.
37.
Athyros VG, Tziomalos K., Kakafika AI, Koumaras H., Karagiannis A., Mikhailidis DPEffectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol . 2008;101(4):483-485.
38.
Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DPEffect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin . Curr Med Res Opin. 2007;23(9):2183-2192.
39.
Tziomalos K. , Athyros VG, Mikhailidis DPStatin discontinuation: an underestimated risk?Curr Med Res Opin. 2008.
40.
Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S.Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008;29(17):2083-2091.
41.
Stancu C., Sima A.Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378-387.
42.
Gadarla M., Kearns AK, Thompson PDEfficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008;101(12):1747-1748.
43.
Crane FLBiochemical functions of coenzyme Q10. J Am Coll Nutr. 2001;20(6):591-598.
44.
Ellis CJ, Scott R.Statins and coenzyme Q10. Lancet. 2003; 361(9363):1134-1135.
45.
Bonakdar RA, Guarneri E.Coenzyme Q10. Am Fam Physician. 2005;72(6):1065-1070.
46.
Davidson MH, Armani A., McKenney JM, Jacobson TASafety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A): 3C-18C.
47.
Chang JT, Staffa JA, Parks M., Green L.Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13(7): 417-426.
48.
Prueksaritanont T., Zhao JJ, Ma B., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301(3):1042-1051.
